Digital Education Hubs
Lipid Management in the Post-ACS Patient
Salim S. Virani,
Watch Drs. Ballantyne, Taub, and Virani discuss some practical pearls about the optimization of lipid-lowering therapy in patients with a recent MI or an acute coronary syndrome (ACS) event. They discuss suboptimal LDL-C levels in these patients, reasons for these gaps, and how to lower LDL-C levels early and effectively with evidence-based therapies in order to minimize the risk of recurrent events. (Recorded June 20, 2022).
CMHC Annual 2021 Lipid Management Panel
CMHC Chairs Christie Ballantyne, MD and Robert Eckel, MD, as well as CMHC faculty Matthew Budoff, MD recap the lipid sessions presented at the 16th Annual CMHC, including perspectives and clinical pearls on ASCVD risk assessment, residual ASCVD risk, and ASCVD management and prevention.
Lipid Management in Very High-Risk Patients Post-MI: Expert Perspectives with Drs. Taub, Desai, Shapiro
MD, MPH, FACC
DO, MCR, FACC, FAHA
Watch Drs. Taub, Desai, and Shapiro discuss some additional perspectives on the management of very high-risk, including:
- The safety of very low LDL-C
- Concerns with statins and new-onset diabetes and how to address overall patient concerns about lipid-lowering therapy
- Residual ASCVD risk beyond LDL-C